Beginning December. 31, 2001, and semi-annually thereafter, Licensee shall submit to The Regents a written progress report covering Licensee’s (and any Affiliate’s or sublicensee’s) activities related to the development and testing of all Licensed Product and the obtaining of the governmental approvals necessary for marketing. Progress reports are required for each Licensed Product.
Appears in 2 contracts
Samples: Exclusive License Agreement (Salmedix Inc), Exclusive License Agreement (Salmedix Inc)
Beginning December. 31, 2001, 1998 and semi-annually thereafter, Licensee shall submit to The Regents a written progress report covering Licensee’s 's (and any Affiliate’s Affiliate or sublicensee’s's) activities related to the development and testing of all Licensed Product Products and the obtaining of the governmental approvals necessary for marketing. Progress reports are required for each Licensed ProductProduct until the first commercial sale of that Licensed Product occurs in the United States.
Appears in 2 contracts
Samples: Exclusive License Agreement (Atherogenics Inc), Exclusive License Agreement (Atherogenics Inc)
Beginning December. 31, 2001, and semi-annually thereafter, Licensee shall submit to The Regents a written progress report covering Licensee’s (and any Affiliate’s or sublicensee’s) activities related to the development and testing of all Licensed Product and the obtaining of the governmental approvals necessary for marketing. Progress reports are required for each Licensed ProductProduct until the first commercial sale of that Licensed Product occurs in the U.S. and shall be again required if commercial sales of such Licensed Product are suspended or discontinued.
Appears in 1 contract